Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma
Stock Information for Oncolytics Biotech Inc.
Loading
Please wait while we load your information from QuoteMedia.